<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614441</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0393</org_study_id>
    <nct_id>NCT04614441</nct_id>
  </id_info>
  <brief_title>NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib.</brief_title>
  <official_title>Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) /&#xD;
      Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing&#xD;
      Interstitial Lung Disease (PF-ILD) patients treated with nintedanib and biomarkers associated&#xD;
      with the disease course, a non-interventional, 3-year, prospective study will be conducted to&#xD;
      collect the long-term real-world clinical data on IPF/SSc-ILD/PF-ILD patients newly&#xD;
      administered with nintedanib in Taiwan&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2020</start_date>
  <completion_date type="Anticipated">July 13, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annual percentage of decline from baseline in Forced Vital Capacity (FVC, %) per cohort of IPF, SSc-ILD, or PF-ILD</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>IPF: Idiopathic Pulmonary Fibrosis PF-ILD: Progressive Fibrosing Interstitial Lung Disease SSc-ILD: Systemic Sclerosis-associated-Interstitial Lung Disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual decline from baseline in Diffusing capacity of the Lungs for Carbon monoxide (DLco, %)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual decline from baseline in resting and exercise Oxygen Saturation (SpO2, %)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first acute exacerbation (AE) of IPF; or time to ILD worsening for SSc-ILD/PF-ILD after study enrollment</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual change from baseline in St George's Respiratory Questionnaire (SGRQ) for IPF or King's Brief Interstitial Lung (K-BILD) for other ILDs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>IPF: Idiopathic Pulmonary Fibrosis ILD: Interstitial Lung Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual change from baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual change from baseline in Six-Minutes Walking Test (6MWT)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual change from baseline in Berlin questionnaire</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quantification of biomarkers</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Biomarkers include but not limited to Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Transforming Growth Factor β1 (TGF-β1), Hepatocyte Growth Factor (HGF), Matrix Metalloproteinase (MMP): MMP-1, MMP-7, MMP-9, α-defensin 1, High Mobility Group Box 1 (HMGB1), Tissue of Metalloproteinase (TIMP), Heat-Shock Protein (HSP): HSP-27, bile acid conjugated, Lysophosphatidic Acid (LPA), Lysophosphatidic Acid Receptor 1 (LPAR1), Prostagladin E2 (PGE2), Interleukin (IL): IL-1β, IL-4, IL-18, IL-13, IL-17, Monocyte Chemoattractant Protein 1 (MCP-1), Macrophage Inflammatory Protein 2 (MIP-2), periostin, osteopontin, Surfactant Protein A (SPA), Surfactant Protein D (SPD), Krebs von den Lungen 6 / Mucin 1 (KL-6/MUC1), anti-HSP70 Immunoglobolin (IgG), Bone Morphogenic Protein (BMP), Carbonhydrate Antigen-199 (CA-199), C-Reaktiv Protein degraded by MMPs (CRPM), chemokine ligand (CCL): CCL 2, CCL-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (with cause of death): respiratory- and non-respiratory-related death</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Idiopathic Pulmonary Fibrosis (IPF)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Progressive Fibrosing Interstitial Lung Disease (PF-ILD)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFEV®</intervention_name>
    <description>nintedanib</description>
    <arm_group_label>Idiopathic Pulmonary Fibrosis (IPF)</arm_group_label>
    <arm_group_label>Progressive Fibrosing Interstitial Lung Disease (PF-ILD)</arm_group_label>
    <arm_group_label>Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study plans to enroll approximately 500 patients with Idiopathic Pulmonary Fibrosis&#xD;
        (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive&#xD;
        Fibrosing Interstitial Lung Disease (PF-ILD) who newly initiate nintedanib per physicians'&#xD;
        discretion within 6 months before participating in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        This study plans to enroll approximately 500 patients with IPF/SSc-ILD/PF-ILD who newly&#xD;
        initiate nintedanib per physicians' discretion within 6 months before participating in the&#xD;
        study.&#xD;
&#xD;
        IPF cohort:&#xD;
&#xD;
          -  Diagnosed with IPF during the prior 6 months before study enrollment, based on the&#xD;
             2018 ATS/ERS/JRS/ALAT guideline&#xD;
&#xD;
          -  Patient ≥ 40 years of age&#xD;
&#xD;
          -  Newly initiating nintedanib within 6 months prior to participating in the study&#xD;
&#xD;
          -  Providing written informed consent prior to participating in the study&#xD;
&#xD;
          -  Having further follow-up possibility with participating physician during the planned&#xD;
             study period&#xD;
&#xD;
          -  Ability to read and write in local language&#xD;
&#xD;
        SSc-ILD cohort:&#xD;
&#xD;
          -  Diagnosed with SSc-ILD during the prior 6 months before study enrollment, based on&#xD;
             2013 ACR/EULAR&#xD;
&#xD;
          -  Patient ≥ 20 years of age&#xD;
&#xD;
          -  Newly initiating nintedanib OR not receiving nintedanib per physician's discretion&#xD;
             (For patients who diagnosed with SSc-ILD but are not treated with nintedanib on&#xD;
             physician's discretion, they will apply the same inclusion criteria, with baseline&#xD;
             characteristics collected only) within 6 months prior to participating in the study&#xD;
&#xD;
          -  Providing written informed consent prior to participating in the study&#xD;
&#xD;
          -  Having further follow-up possibility with participating physician during the planned&#xD;
             study period&#xD;
&#xD;
          -  Ability to read and write in local language&#xD;
&#xD;
        PF-ILD cohort:&#xD;
&#xD;
          -  Diagnosed with PF-ILD (PF-ILD patients will be enrolled only after nintedanib acquires&#xD;
             the label approval from TFDA) during the prior 6 months before study enrollment. The&#xD;
             definition of PF-ILD diagnosis is as follows:&#xD;
&#xD;
             --Patients who have ILD with a progressive phenotype, but are not diagnosed with IPF,&#xD;
             per physician's judgment. The pathophysiology in these patients is characterized by&#xD;
             self-sustaining fibrosis and a deterioration in lung function over time, with&#xD;
             worsening respiratory symptoms, resistance to immune-modulatory therapies, and&#xD;
             ultimately early mortality.&#xD;
&#xD;
          -  Patient ≥ 20 years of age&#xD;
&#xD;
          -  Newly initiating nintedanib OR not receiving nintedanib per physician's discretion&#xD;
             (For patients who diagnosed with PF-ILD but are not treated with nintedanib on&#xD;
             physician's discretion, they will apply the same inclusion criteria, with baseline&#xD;
             characteristics collected only) within 6 months prior to participating in the study&#xD;
&#xD;
          -  Providing written informed consent prior to participating in the study&#xD;
&#xD;
          -  Having further follow-up possibility with participating physician during the planned&#xD;
             study period&#xD;
&#xD;
          -  Ability to read and write in local language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Lung transplantation expected within the next 6 months.&#xD;
&#xD;
        --Included in ongoing interventional trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang-Hua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Hsiung Lin</last_name>
      <phone>+886-910-440307</phone>
      <email>47822@cch.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Chiayi</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh-Mo Lin</last_name>
      <phone>+886-5-3621000ext2762</phone>
      <email>jamesnomo@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital-Hsin-Chu Branch</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueh-Feng Wen</last_name>
      <phone>03-5326151#2027</phone>
      <email>freeman0509@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin Bin Lin</last_name>
      <phone>03-8561825#2118</phone>
      <email>ferlin@tzuchi.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Feng Wei</last_name>
      <phone>+886-9-7510-6137</phone>
      <email>yufeng528@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng-Chih Lin</last_name>
      <phone>0975-056-028</phone>
      <email>mengchih@adm.cgmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chau-Chyun Sheu</last_name>
      <phone>886-7-3121101#5901</phone>
      <email>?Sheucc@gmail.com?</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuo-An Chu</last_name>
      <phone>0975-581-117</phone>
      <email>kachu@vghks.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Lung Cheng</last_name>
      <phone>02-89667000ext2816</phone>
      <email>shihlungcheng@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang-Yun Lee</last_name>
      <phone>02-22490088#7515</phone>
      <email>13258@s.tmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Tzu Chi General Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Yao Huang</last_name>
      <phone>886970333787</phone>
      <email>huang6693@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asia University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien Wen Huang</last_name>
      <phone>04-37061668#1878</phone>
      <email>hjwn0403@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheng Ching Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tu-Chen Liu</last_name>
      <phone>0936-972-402</phone>
      <email>Liou.dj@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Yen Tu</last_name>
      <phone>04-22052121#4670</phone>
      <email>D7855@mail.cmuh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Ming Tsao</last_name>
      <phone>0928058232</phone>
      <email>tsmhwy@ms24.hinet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeng-Yuan Hsu</last_name>
      <phone>04-23592525#4039</phone>
      <email>hsujy@vghtc.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Li Chung</last_name>
      <phone>0970-405-068</phone>
      <email>clchung@tmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardinal Tien Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Yi Wang</last_name>
      <phone>0910-086180</phone>
      <email>cywang@mospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin Rehabilitation Medical Center</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Wei Tao</last_name>
      <phone>(02)28264400#2500</phone>
      <email>davidtao_2001@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Lung Liu</last_name>
      <phone>(02)28094661</phone>
      <email>clliu.5839@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao-Chien Wang</last_name>
      <phone>886-2-23123456#67773</phone>
      <email>haochienwang@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-wung Yeh</last_name>
      <phone>0984-160-130</phone>
      <email>m004917@ms.skh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perng Diahn Warng</last_name>
      <phone>(02)2871-2121#7034</phone>
      <email>dwperng@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Kan Peng</last_name>
      <phone>02-8792-3311#13482</phone>
      <email>kanpeng1025@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taitung MacKay Memorial Hospital</name>
      <address>
        <city>Taitung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsin-hung Wu</last_name>
      <phone>(089)310150#482</phone>
      <email>a5809@mmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TaoYuan General Hospital</name>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Wei Lee</last_name>
      <phone>(03)3699721</phone>
      <email>chestman9@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital(Linkou)</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuo-Chin Kao</last_name>
      <phone>(03)328-1200#2281</phone>
      <email>kck0502@cgmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Yang-Ming University Hospital</name>
      <address>
        <city>Yilan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Chieh Chang</last_name>
      <phone>03-9325192#13900</phone>
      <email>dtsurga9@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Yun-Lin Branch</name>
      <address>
        <city>Yunlin County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen-Fu Chen</last_name>
      <phone>05-5323911#2325</phone>
      <email>yenfu1228@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.&#xD;
.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'.For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

